B7-33 (Relaxin) record · updated 20h ago

Healing & recoveryInflammation & immuneGrade A · human clinicalResearch use only

All 5 studies Jump to the evidence Compare

What is B7-33 (Relaxin) used for?

B7-33 is a single-chain peptide analog of relaxin-2 designed to retain anti-fibrotic and vasodilatory signaling while simplifying synthesis. It is investigational and research-use only.

Primarily researched for · Healing & recovery

Development stage

where B7-33 (Relaxin) sits between preclinical work and regulatory approval

1Cleared
Preclinical
Animal / in-vitro work
2Cleared
Phase 1
Safety in humans
3Current
Phase 2
Efficacy signal
4Not reached
Phase 3
Confirmatory trials
5Not reached
Approved
Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 10 registered trials. It describes the research record, not a recommendation.

Identity

NameB7-33 (Relaxin)

Chain length—

Molecular weight—

Formula—

Structure type—

ClassHealing

Research levelPreclinical

Discovered byCurated master list · 2026

Pharmacology

Mechanism—

Route—

Half-life—

Time to peak—

Duration—

Extraction confidence—

Effect profile · 0–5

These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Aug 23, 2026. How this works →

Research stats

Total studies5

Human / animal / cellular5 / 0 / 0

Highest trial phasePhase 2

Years covered2026

Latest study3d ago

Publication history

20262026

Research funding

12 NIH projects · $4.3M awarded · through FY2026

Public grants naming this compound. Funding is interest, not evidence.

Safety signals

FAERS reportsnone recorded

Serious AEs in animal work—

Community reports—

Positive —Neutral —Negative —

Records

ChEMBL ClinicalTrials.gov DrugBank Google Scholar PubChem PubMed · 5 Semantic Scholar UniProt

Study register

5 rowsOpen in the library →

SortDate added ↓Publication year Evidence type Summary depth

Study	Type	Year	Summary depth
Heterozygous germline <i>MSH3</i> mutations, and probably <i>MLH3</i> mutations, act as classical tumour suppressors, leading to excess somatic deletion mutations, signature ID4 and increased colorectal cancer risk Finding2.2-fold increased risk of CRC for heterozygous MSH3 mutations, P=6.6x10^-5	Human	2026	Full text read0.80
A conserved grain-associated immunosuppressive niche in Sudanese patients with mycetoma FindingNot reported in abstract.	Human	2026	Full text read0.70
Sex-based considerations in the choice for a TLR9 or TLR7/8 agonist to arm the sentinel lymph node in early-stage melanoma. FindingNot reported in abstract.	Human	2026	Full text read0.70
A relative methylation ordering biomarker of lactylation-related genes predicts prognosis and therapeutic response in cutaneous melanoma. FindingKaplan-Meier log-rank test, p=0.046 for survival differences between clusters.	Human	2026	Full text read0.80
Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies. FindingMedian OS not reached vs 15.3 months; HR=0.58; 95% CI, 0.36-0.96; p=0.03.	Human	2026	Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching B7-33 (Relaxin) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much B7-33 (Relaxin) is discussed should be drawn from it.